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Although the World Health Organization (WHO) de-
clared global smallpox eradicated in 1980, concerns over 
emergent poxvirus infections have increased. Most poxvirus 
infections are zoonotic; exploring their genetic diversity will 
illuminate the genetic and evolutionary aspects of poxvirus 
infections, ecology, and epidemiology. In recent decades, 
several strains of the orthopoxvirus vaccinia virus (VACV) 
have been isolated throughout Brazil, including genetically 
distinct isolates within the same outbreak. To further investi-
gate the diversity and origins of these viruses, we analyzed 
molecular data from 8 Brazilian VACV isolates and com-
pared several genes involved in virus structure and patho-
genicity. Genetic variation among isolates suggests that an-
cestral Brazilian VACVs existed before the beginning of the 
WHO smallpox eradication vaccination campaigns and that 
these viruses continue to circulate.
I
n 1980, the World Health Organization (WHO), after a 
massive vaccination program, announced the eradication 
of smallpox, the contagious and deadly disease caused by 
variola virus (VARV). This program used live vaccinia vi-
rus (VACV), a virus from the same genus, Orthopoxvirus, 
which shares a high degree of immunologic cross-reactiv-
ity with VARV. Recent reports of cowpox virus (CPXV) 
infections in Europe, monkeypox virus (MPXV) outbreaks 
in Africa and the United States, and the surprising emer-
gence of VACV in Brazil highlight the need for continued 
research into the ecology, epidemiology, origin, and evolu-
tion of these viruses (1).
The known history of VACV species imported to Bra-
zil dates back to 1804, when human vaccine arrived at a 
port in Bahia State on the arms of slaves returning to Bra-
zil from Lisbon, Portugal (2) (Figure 1). From Bahia State 
the slaves were sent south to Rio de Janeiro State, possibly 
passing the vaccine to local people as they made their way 
through the region. Indeed, from 1804 to 1887, the Brazilian 
population (including slaves and other people living in the 
countryside) was vaccinated in this manner, arm to arm. In 
some cities, vaccination was obligatory, beginning in 1832. 
In 1887, the ﬁ  rst animal vaccine produced in calves was 
imported in ﬂ  asks to the vaccine institute in Rio de Janeiro 
(now Oswaldo Cruz Institute) from the Chambon Institute 
in Paris, France (2). The vaccine was then distributed to 
other states across Brazil, including Minas Gerais, Espirito 
Santo, São Paulo, Mato Grosso, Rio Grande do Sul, and 
Pernambuco (2). During this time, between 1887 and 1895, 
vaccine institutes were established in these states (2).
Published accounts of Brazilian vaccinia-like viruses 
isolated from sentinel mice and recent outbreaks on dairy 
farms affecting cattle and their handlers suggest the once-
emergent disease has now become endemic (4–13). We com-
bined historical information and published data to develop 
insights into the possible origin(s) of the Brazilian VACV 
(BRZ-VACV) now established in Brazil. Our goal was to 
determine whether BRZ-VACV represents an escaped vac-
cine strain, an autochthonous orthopoxvirus, or both.
Methods
We examined the sequence diversity of 8 geographi-
cally and temporally variable BRZ-VACV isolates. We 
compared molecular sequence data from 3 genes and a 
variable region of the poxvirus genome (Table 1) among 
BRZ-VACV isolates, available vaccine strains related to 
those used during the eradication campaign in Brazil, and 
other VACVs isolated from domestic animals (including 
endemic buffalopox virus in India [15–17] and horsepox 
virus [HSPV] from Asia [18]). 
Sequences were collected from GenBank (Tables 1 
and 2). Some isolates had limited sequence data for the 
4 genes examined. Although all 4 genes are not available 
from Lister (B19R gene is not present in the Lister ge-
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nome), the Lister isolate was included because of its im-
portance in the history of vaccination in Brazil (3,6). Se-
quences from 3 genes were manually aligned and trimmed 
to include only the regions available for all isolates (VACV-
COP A56R 161210–162095, E3L 51465–50929, B19R 
178242–179173). Nucleotide identities were calculated by 
using BioEdit (www.mbio.ncsu.edu/bioedit/bioedit.html) 
(online Technical Appendix, available from www.cdc.
gov/EID/content/13/7/965-Techapp.pdf). PAUP* version 4 
(Sinauer Associates; Sunderland, MA, USA) and MrBayes 
3.1 (http://mrbayes.csit.fsu.edu) were used to analyze a ma-
trix of the 3 concatenated genes (19,20). Parsimony analysis 
was performed on 1,000 random addition replicates. Ap-
propriate models of sequence evolution were determined 
by Modeltest (21) with the Akaike information criterion 
(22,23). The identiﬁ  ed model was then applied to maximum 
likelihood and Bayesian analyses. In MrBayes, the Markov 
chain Monte Carlo searches explored 4 chains for 1 mil-
lion generations, sampling every 100 generations. Sample 
points during the ﬁ  rst 50,000 generations were discarded as 
burn-in, before which the chain reached stationarity (ﬁ  xed 
condition). To account for any considerable rate variation 
between genes, a second Bayesian analysis was run wherein 
each gene was partitioned and allowed to vary indepen-
dently (MrBayes command: prset ratepr = variable). DNA 
sequence data for the fourth coding region, rpo132-ATI-
p4c-A27 (A-type inclusion body gene), were not included 
in the phylogenetic analysis; however, published digestion 
proﬁ  les from relevant strains were compared. 
Results
The resultant phylogenetic tree (Figure 2A) depicts 
several highly supported clusters including monophyletic 
VACV, MPXV, VARV, and camelpox virus (CMLV) assem-
blages. VARV and CMLV isolates are depicted as sister taxa 
with high support. Brazilian isolates fall into 2 well-sup-
ported monophyletic groups. Group 1 comprises Araçatuba 
virus (ARAV), Cantagalo virus (CTGV), Guarani P2 virus 
(GP2V), and Passatempo virus (PSTV); group 2 comprises 
GP1V, Belo Horizonte virus (VBH), BeAn 58058 virus 
(BAV), SPAn232 virus (SAV), and VACV-Western Reserve 
(WR). Results of all analyses—parsimony, maximum like-
lihood, and Bayesian analysis (data not shown)—all gener-
ated 2 distinct Brazilian clades and indicated a close rela-
tionship between group 2 and VACV-WR. Neither group 
of BRZ-VACV was directly linked with VACV-Oswaldo 
Cruz Institute (IOC) or VACV-Lister in any analysis. Both 
BRZ-VACV groups are represented by 4 isolates each. 
VACV-Acambis3000 and VACV-modiﬁ  ed vaccinia Ankara 
(MVA) group together with high support (98, Figure 2A), 
which reﬂ  ects their derivation from vaccinia isolate An-
kara (both are virus isolates of MVA). Isolates with known 
origins from Dryvax (Wyeth Laboratories, Marietta, PA, 
USA) (VACV-3737, -Acambis3, -Acambis2000, -DUKE) 
did not group together consistently. This could be a result 
of numerous passages, the history of Dryvax as a nonclonal 
vaccine strain, or both.
Genetic comparisons of the analyzed VACV strains can 
be seen in the online Technical Appendix. For BRZ-VACV 
at all 3 loci, the highest identity values occurred within 
Figure 1. Timeline of events regarding the introduction and 
circulation of orthopoxviruses in Brazil (2,3). Double slashes 
indicate a gap in the timeline.
Table 1. Single gene sequences of Vaccinia viruses included in this study  
Gene and GenBank accession no.* 
Strain, isolate (abbreviation)  A56R B19R E3L Rpo132-ATI-p4c-A27L 
BeAn 58058 virus (BAV)  DQ206442  AF261890 DQ194388  NA
SpAn232 virus (SAV)  AF261890 DQ194384  DQ194387  NA
Belo Horizonte (VBH)  DQ206435  DQ194383  DQ194390  AF501620
Guarani P1 virus (GP1V)  DQ206436  DQ194380  DQ194385  DQ363383 
Guarani P2 virus (GP2V)  DQ206437  DQ194381  DQ194386  NA
Araçatuba virus (ARAV)  AY523994  DQ194382  DQ194389  NA
Passatempo virus (PSTV)  DQ070848  DQ530239  DQ530240  NA
Cantagalo virus (CTGV)  AF229247 AY500815  AY771338  NA
Malbran virus (VACV-Malbran)  AY146624  NA NA NA
Vaccinia virus-Oswaldo Cruz Institute (VACV-IOC)   AF229248 AY500816  DQ070236  NA
BFL-3906 AF375077 NA NA NA
BFL-81 AF375078 NA NA NA
Wyeth Z99051 Not included NA NA
*Reference: Vaccinia Copenhagen. A56R, viral hemagglutinin; B19R, soluble alpha/beta interferon [IFN] receptor; E3L, dsRNA-binding protein; rpo132-
ATI-p4c-A27L, a region that codes for the major protein of the A-type inclusion body (14); NA, not available. Brazilian Vaccinia Viruses and Their Origins
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each phylogenetic group. The E3L sequence of PSTV is 
the only exception. The PSTV E3L sequence is identical to 
those of GP1 and WR and showed the next highest identity 
level with the VBH sequence. This ﬁ  nding may indicate re-
combination in this portion of the genome between isolates 
from these 2 groups. Additional genomic data and analysis 
are needed.
The sequence diversity of the orthopoxvirus hemag-
glutinin (HA) gene has made it a potential marker for mo-
lecular diagnostics and phylogenetics (24). In particular, 
an 18-nt deletion within the gene has been proposed as an 
identiﬁ  er of BRZ-VACV strains (8,11,25). A recent article 
describes 2 approaches for identifying BRZ-VACV–like 
isolates (25), both of which rely on presence of the 18-nt 
deletion. Figure 3 shows that while some Brazilian strains 
(ARAV, CTGV, GP2V, PSTV) share this deletion, others 
(SAV, BAV, GP1V and VBH) do not and would not be 
detected by these methods. Within the variably deleted re-
gion (Figure 3, amino acids 245–255), VACV isolates can 
be grouped into 4 types; Brazilian isolates fall into 2 of 
these. Rabbitpox virus from Utrecht has a unique deletion 
of only 2 residues (254, 255); VACV-3737 and VACV-Mal-
bran share a 5–amino acid deletion (245–249). The VACV-
3737 isolate was “plaque-puriﬁ  ed from a vaccinia lesion 
following vaccination with Dryvax” (GenBank,accession 
no. DQ377945); VACV Malbran was used in vaccination 
programs in Argentina between 1937 and 1970 (27). GP1V 
and VBH share the same amino acid sequence (ADLY-
DTYNDND; 245–255), identical to that of VACV-WR, 
VACV-Lister, and several other strains. The remaining 
isolates from Brazil share the familiar deletion of 6 amino 
acids (250–255) described previously. This deletion is also 
present in the VACV-IOC vaccine isolate (absent in Lister 
and VACV-WR). The variation in this region demonstrates 
that the deletion itself is not representative of all Brazilian 
isolates and therefore is not useful as an identiﬁ  er of Brazil-
ian VACV.
This same deletion has been recognized as a possible 
shared derived trait between VAVC-IOC and BRZ-VACV. 
Although this scenario is indeed possible for the CTGV-
like BRZ-VACV of group 1, those isolates of group 2 are 
unlikely to be derived from the IOC vaccine strain because 
this strain does not carry the insertion. Furthermore, an-
other variable gap occurs in this region of HA among iso-
lates derived from VACV-Lister and Dryvax (New York 
City Board of Health [NYCBH]). Some clones present the 
deletion; others do not. The sequence can be found directly 
adjacent upstream of the variable deletion of the group 1 
Brazilian isolates (Figure 3). Perhaps this region is nones-
sential and able to easily withstand such variation without 
detrimental effects on the utility of the HA protein or the 
ﬁ  tness of the virus. Regardless, this deletion clearly cannot 
be relied upon to identify isolates directly related to Lister 
or NYCBH strains. A single shared deletion is only 1 char-
Table 2. Complete virus genome sequences of orthopoxviruses 
Species Strain, isolate (abbreviation) GenBank accession no.
3737 (VACV-3737) DQ377945
Acambis 3000 (VACV-Acambis 3000) AY603355
Acambis 2000 (VACV-Acambis 2000) AY313847
Acambis 3 (VACV-Acambis 3) AY313848
Vaccinia DUKE (VACV-DUKE) DQ439815
Lister (VACV-LIS) AY678276
Tian Tan (VACV-TianTan) AY678275
Western Reserve (VACV-WR) AY243312
Modified Vaccinia Ankara (VACV-MVA) U94848
Vaccinia virus
Copenhagen (VACV-COP) M35027
Horsepox virus HPXV MNR-76 (HPXV) DQ792504
Rabbitpox virus  Utrecht (RPXV-UTR) AY484669
Brighton Red (CPXV-BR) AF482758 Cowpox virus 
GRI-90 (CPXV-GRI) X94355
Bangladesh-1975 (VARV-BSH 75) L22579
Garcia-1966 (VARV-GAR) X76266
Variola virus
India-1967 (VARV-IND) X69198
Congo_2003_ (MPX-RCG 2003) DQ011154
Liberia_1970_184 (MPXV-LIB 1970) DQ011156
USA_2003_039 (MPXV-USA 2003 039) DQ011157
WRAIR7-61 (MPXV-61 WR) AY603973 
Zaire_1979-005 (MPXV-ZAI 1979) DQ011155
Monkeypox virus
Zaire-96-I-16 (MPXV-ZAI 1996) AF380138
Ectromelia virus Moscow (ECTV-MOS) AF012825
CMS (CMLV-CMS) AY009089 Camelpox virus 
M-96 (CMLV-M96) AF438165PERSPECTIVE
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acter toward determining phylogenetic relatedness among 
strains. If smallpox vaccines are not clones but rather pools 
of virions that vary at the molecular level, assuming relat-
edness based on a single molecular variation is even more 
difﬁ   cult. Our phylogenetic analyses of 302 informative 
characters, including variation across the HA gene, does 
not indicate a close relationship between VACV-IOC and 
BRZ-VACV. The consensus tree (Figure 2A) depicts the 
IOC vaccine strain in an unresolved basal polytomy within 
the vaccinia cluster and is thus inconclusive as to the relat-
edness of VACV-IOC and BRZ-VACV.
Finally, published data indicate a large amount of vari-
ability in the region that includes the A-type inclusion body 
gene of the BRZ-VACV isolates (5,9,11–13). Figure 3B 
illustrates the arrangement of open reading frames in this 
region (rpo132-ATI-p4c-A27L) for CPXV Brighton Red, 
VACV Copenhagen, VACV-WR, and BRZ-VACV. The 
formation of A-type inclusion bodies is restricted to cells 
infected with CPXV, ectromelia virus, and raccoonpox 
virus. The C-terminus of the gene encoding the ATI pro-
tein is highly conserved among orthopoxviruses because 
it overlaps with the C-terminus of the RNA polymerase 
(132) coding region (9,13). However, the region between 
this conserved sequence and the N-terminus of the P4c pre-
cursor shows considerable variation among orthopoxvirus 
strains (26). Deletions and nucleotide changes generate 
variable coding regions and distinguishable digest patterns 
in this portion of the genome. Three proﬁ  les of this region 
have been discerned among BRZ-VACV; 2 are differentiat-
ed by distinct digestion patterns (6,7,11,13). The third state 
is the near complete absence of the A26L gene except for 
the last 112 nt (9,13). According to da Fonseca et al., SAV, 
a Brazilian VACV isolate, shows an A26L digestion pro-
ﬁ  le identical to that of the VACV-WR strain (proﬁ  le 1) (6). 
ARAV, PSTV, and GP2V show a digestion proﬁ  le compat-
ible with but not identical to that of the SAV, VACV-WR, 
and Lister strains (proﬁ  le 2) (7,11,13). In BAV, VBH, and 
GP1V, a major portion of the A26L gene is missing (proﬁ  le 
3) (5,9,13). The open reading frame is small and is probably 
not expressed, although this has not been veriﬁ  ed by North-
ern or Western blot. Damaso and colleagues demonstrated 
that A26L is present in CTGV; however, the digestion pro-
ﬁ  le has not been established. Western blot analysis detected 
a 94-kDa protein typical of VACV-WR and VACV-IOC 
(8). These 3 proﬁ  les correspond to 3 clades recovered in 
the phylogenetic tree (Figure 2A). These ﬁ  ndings consti-
tute  a major distinction between CTGV (also SAV, ARAV, 
PSTV, and GP2V, which exhibit proﬁ  les 1 and 2) and the 
other Brazilian isolates BAV, VBH, and GP1V (proﬁ  le 3). 
Furthermore, the unusual deletion presented by BAV, VBH, 
and GP1V is remarkably different from the corresponding 
regions of VACV-IOC, -WR, and -Lister, strains implicated 
in the release of VACV in Brazil.
Figure 2. A) Strict consensus of the 6 most parsimonious trees 
derived from Orthopoxvirus species on the basis of B19R, E3L, and 
A56R sequences and rooted with ectromelia virus from Moscow 
(ECTV-MOS). Bootstrap values based on 100 bootstrap replicates 
of 10 random addition replicates each are shown at each node 
where the value was >50%. Black rectangles represent the 18-nt 
deletion shared by group 1 Brazilian vaccinia virus (BRZ-VACV) and 
VACV-Institute Oswaldo Cruz (IOC) and where it maps on the tree. 
Open rectangles represent the 3 digestion proﬁ  les (P1, P2, and P3) 
of the rpo132-ATI-p4c-A27L region assigned at each appropriate 
node. Blue, branches of group 1; red, branches of group 2; orange, 
isolation of VACV-Guarani P1 (GP1) and VACV-GP2 at adjacent 
farms in the same area. Colors correspond to information presented 
in panel B. B) Map of Brazil showing states and ecological biomes. 
Collection sites are represented by numbers that refer to Brazilian 
isolates and their respective years of isolation. Map used with 
permission from Instituto Brasileiro de Geograﬁ  a e Estatistica. GO, 
Goiás; SP, São Paulo; MG, Minas Gerais. See Table 2 for other 
deﬁ  nitions.Brazilian Vaccinia Viruses and Their Origins
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Discussion
Although eradication had been achieved in Europe by 
1953 and in Central and North America by 1951, Brazil 
did not conduct a nationwide vaccination campaign during 
the 1950s. However, Brazilian people in cities and towns 
were vaccinated when outbreaks were reported by local 
authorities (2,3). Not until 1962 did Brazil, working with 
the Pan American Health Organization, launch a national 
campaign against smallpox (3). The intensiﬁ  ed  global 
WHO program prompted a renewed national program in 
Brazil in 1966. Fenner et al. (3) present a sample question-
naire that the smallpox eradication unit circulated in 1967 
to all vaccine producers in countries accessible to WHO. 
In Brazil, this included 4 laboratories in different regions: 
the IOC, the Butantan Institute in São Paulo, the Institute 
for Biological Research in Porto Alegre, and an institute in 
the town of Recife, Pernambuco State (3). Records iden-
tify the seed strains used at these institutes to be “Paris,” 
Lister, and “Lederle” (28). “Paris” appears to be a reference 
to the original animal vaccine imported from the Chambon 
Institute in 1887. The Institute for Biological Research in 
Porto Alegre received from London the Lister strain, which 
was originally developed at the Lister Institute, England. 
Recife and Butantan both indicated use of a strain obtained 
from Wyeth’s Lederle Laboratory in the United States. The 
NYCBH strain was the source of Lederle and forerunner 
of Dryvax, the live vaccine maintained in the United States 
since the 1970s, and the research vaccine strain VACV-WR 
(3). These records conﬁ  rm information that “Paris,” Lister, 
and NYCBH were used in Brazil between 1968 and 1971 
(2,3). It has been suggested that VACV-WR was used as a 
vaccine in Brazil as well; however, such use is now thought 
to be unlikely (6,7). The strain was derived by serial pas-
sage in mice infected intracranially and selected for neural 
virulence to mimic encephalitis, a rare side effect of the 
vaccine in humans (29,30). When available vaccine sup-
plies dropped to critical levels in 1970, Brazil requested 
and received reserve vaccine from Argentina at least once 
(3). The Malbran strain was used in vaccination programs 
in Argentina until 1970, after which the Lister strain was 
adopted following WHO recommendations (2,3,27). Vac-
cine production at the Butantan Institute converted to the 
Lister strain late in 1970 (3), and Butantan became the of-
ﬁ  cial distributor for Brazil. Therefore, at least 4 strains of 
vaccine might have been distributed within Brazil during 
the WHO eradication campaign.
Discovery of Brazilian VACV Isolates
Since the 1960s, orthopoxviruses have been repeatedly 
isolated in Brazil and identiﬁ  ed as VACV by classical im-
munologic, virologic, and molecular methods (4–13,26). In 
1963, BAV was isolated from the blood of a rice rat (Ory-
zomys sp.) captured near the edge of a deforested area bor-
dered by Amazon rain forest (Figure 2B) (4,5). This virus 
Figure 3. A) Partial amino acid alignment of A56R vaccinia virus Copenhagen (VACV-COP). Sequences were retrieved from GenBank 
and aligned using the BioEdit program (www.mbio.ncsu.edu/bioedit/bioedit.html). VACV-COP (M35027, 161908-161957) is used as the 
reference sequence; International Union of Pure and Applied Chemistry symbols, amino acids; dots, residues identical to the reference 
sequence; dashes, gaps created by the alignment; gold box surrounds the 18-nt deletion once proposed as a Brazilian (BRZ)-VACV 
molecular identiﬁ  er. RPXV-UTR, rabbitpox virus-Utrecht; HSPV, horsepox virus; MVA, modiﬁ  ed vaccinia Ankara; LIVP, Liverpool; BFL, 
buffalopox; BAV, BeAn 58058 virus; SAV, SpAn232 virus; VBH, Belo Horizonte virus; GP, Guarani; ARAV, Araçatuba virus; CTGV, Cantagalo 
virus; PSTV, Passatempo virus;  IOC, Institute Oswaldo Cruz. B) Depiction of the rpo132-ATI-p4c-A27 region in cowpox virus Brighton 
Red (CPXV-BR) and VACV strains. Positions of primers RNApol, ATI-low, ATI-up, and P4c1 are illustrated. These primers have been used 
for the molecular diagnosis of Brazilian (BRZ)-VACV (5,26). The 300-bp fragment ampliﬁ  ed by primers RNApol and P4c1 from GP1V and 
VBH was sequenced by Trindade et al. (9,13). Sequence outside this region is unknown. ATI-f is used to designate coding regions that 
resemble fragments of the wild-type (CPXV-BR) ATI gene. The gap in VACV-COP lies within the A26L gene. *This gene is often referred 
to as ATI due to its original description. However, the coding region is actually a fusion of the C-terminus of ATI and the N-terminus of 
P4c where the sequence in between has been deleted. The gene is currently identiﬁ  ed by the Poxviridae Bioinformatics Resource (http://
athena.bioc.uvic.ca/database.php?db=poxviridae) as belonging to the P4c precursor family. †Western Reserve is presumed similar in 
structure to SpAn232 virus, GP2V, ARAV, and PSTV due to similar restriction fragment length polymorphism results (6,7,11,13).  PERSPECTIVE
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is among the ﬁ  rst orthopoxviruses naturally isolated from 
a wild rodent in Brazil (4,5). In the 1960s and 1970s, the 
Brazilian government and the Institute Adolfo Lutz con-
ducted surveillance of arboviral activity in forested areas 
around the city of São Paulo, in the southeastern region of 
the country. During that investigation, a poxvirus was re-
peatedly isolated from sentinel mice and called Cotia virus 
(31). A sample of Cotia, SAV, was sent to the virus labora-
tory in Minas Gerais State. The specimen was plaque puri-
ﬁ  ed in duplicate, and a vaccinialike virus was isolated (6). 
Samples of Cotia have been studied elsewhere, and inde-
pendent characterizations of the virus have been contradic-
tory (32–34). These contradictory ﬁ  ndings suggest that the 
material provided in the original sample(s) contained >1 
virus, leading to conﬂ  icting reports of behavior and sero-
logic relationships. We continue to refer to this sample as 
SPAn232 with reference to de Souza Lopes et al. (31) and 
da Fonseca et al. (6) to distinguish it from other isolates 
described previously.
In 1998, VBH was isolated from frozen clinical sam-
ples collected from mice during a mousepox-like outbreak 
in the animal facility of the Biological Institute of the 
University of Minas Gerais State in 1993 (Figure 2B) (9). 
Exanthematous outbreaks affecting dairy cattle and their 
handlers were reported in Brazil in 1999. Two new VACV 
strains, ARAV and CTGV, were isolated from sick cows 
in distinct geographic locations of the southeast region of 
the country (Figure 2C) (7,8). Since then, an increasing 
number of similar zoonotic outbreaks have been reported 
in different countryside areas of Brazil, particularly the 
southeast and southwest (Figure 2A, B) (10,12). In 2001, 
GP1V and GP2V were isolated from infected cows from 
adjacent farms near the area where CTGV had been found. 
Despite their coincident locale, the 2 new isolates constitute 
distinctly different VACV isolates (Figure 2A, C) (13). In 
2003, PSTV was also isolated from cows in Minas Gerais 
State during a subsequent bovine vaccinia outbreak (Figure 
2C; Table 3 [11]). Isolates from group 1, similar to CTGV, 
have been collected more often than those from group 2 
(10,25), which could reﬂ  ect greater ﬁ  tness, prevalence, or 
virulence associated with group 1; however, any explana-
tion is speculative. The difference might eventually be at-
tributed to an as-yet unidentiﬁ  ed sampling bias.
Isolates have been obtained from 3 of 6 Brazilian bi-
ome types (Figure 2B). Most have been collected in the 
Atlantic Forest region, where much of the forest has been 
cleared for dairy farms and coffee and sugar cane planta-
tions (35). Reported human cases are typically in dairy 
workers, but SAV was isolated from a sentinel mouse 
placed within the Cotia Forest, São Paulo State (6), and 
BAV was obtained from a wild-caught rodent (Oryzomys) 
in northern Brazil. These occurrences, combined with the 
genetically similar isolates from the southern portion of the 
country (2,500 km away), indicate the potential circulation 
of viral strains throughout Brazil and perhaps other regions 
of South America. Moreover, some of these genetically di-
vergent strains have a sympatric distribution, as illustrated 
by the isolation of GP1V (group 2) and GP2V (group 1) 
from adjacent farms (13). Sequencing of the more rapidly 
evolving inverted terminal repeats of the genome would 
help clarify the relationship between BRZ-VACV and its 
hosts. The near-terminal regions of the genome contain 
most genes involved in host interaction (14) and may il-
luminate ways in which the host may have shaped the virus 
evolution. No data are available regarding host variation, 
epidemiology, or evidence of clinical manifestations that 
can distinguish between the 2 genetic BRZ-VACV groups 
depicted in the phylogenetic analyses.
Potential Origins of Brazilian VACV
The possibility that the BRZ-VACV isolates originated 
from the spread of a smallpox vaccine strain, particularly 
Table 3. Brazilian Vaccinia viruses and vaccine strains used in Brazil*  
Virus
Year of 
isolation Source Place of isolation and biome  Reference
VACV-LIS 1870 Prussian soldier Vaccine Institute, Cologne, Germany  (3)
VACV-WR 1876 NYCBH strain  New York City Department of Health Laboratory  (3)
SAV† 1961 Rodent, sentinel mice  São Paulo State, Atlantic tropical rainforest, Brazil  (6)
BAV 1963 Rodent, Oryzomys sp. Para State, Amazon tropical rainforest, Brazil  (4,5)
VBH 1998 Rodent, BALB-c mice  Minas Gerais State, Cerrado woodland/savanna, Brazil  (9)
ARAV 1999 Cow  São Paulo State, Cerrado woodland/savanna Brazil  (7)
CTGV 1999 Cow  Rio de Janeiro State, Atlantic tropical rainforest, Brazil  (8)
GP1V 2001 Cow  Minas Gerais State, Atlantic tropical rainforest, Brazil  (13)
GP2V 2001 Cow  Minas Gerais State, Atlantic tropical rainforest  (13)
PSTV 2003 Cow  Minas Gerais State, Atlantic tropical rainforest, Brazil  (11)
VACV-IOC ND† Probable Paris strain  ND (3,8)
*VACV, vaccinia virus; LIS, Lister; WR, Western Reserve; NYCBH, New York City Board of Health; SAV, SpAn232 virus; BAV, BeAn 58058 virus; VBH, 
Belo Horizonte virus; ARAV, Araçatuba virus; CTGV, Cantagalo virus; GP, Guarani virus; PSTV, Passatempo virus; IOC, Oswaldo Cruz Institute; ND, not 
determined.  
†This virus was studied by the viral laboratory in Minas Gerais State in 1979 and cloned in Vero cells during the 1990s (4). It was originally collected and 
referred to as Cotia virus, which was repeatedly isolated throughout the 1960s and 1970s by the Adolfo Lutz Institute in Brazil (33).Brazilian Vaccinia Viruses and their Origins
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VACV-IOC and VACV-Lister, has been proposed (4,6,8). 
A deletion in HA supports this hypothesis; but the larger 
portion of evidence, the phylogenetic analysis, does not. 
Available data offer no solid support for these proposed 
sources as the origin of BRZ-VACV. The VACV-IOC vac-
cine should be further examined to determine whether it 
contains virions without the 18-nt HA deletion. Historical 
records raise the possibility that strains currently circulating 
in Brazil were established from the original (ﬁ  rst known) 
introduction of VACV to the region by the slave trade in 
the early part of the 19th century, by the introduction of 
the animal-cultivated vaccine in the latter part of the 19th 
century, or subsequently by the wave of VACV introduc-
tion brought through the smallpox eradication program in 
the mid 20th century. If BRZ-VACV was introduced from 
the Old World, multiple introductions from essentially the 
same source region (Europe) over ≈167 years (from at least 
1804 to 1971, when vaccination in Brazil ceased) (2,3,36) 
could be responsible for the observed diversity of BRZ-
VACV. Because the source of the naturally occurring iso-
lates of Brazil may well be the same as that of the vaccine 
strains, the history of this viral species will be difﬁ  cult to 
tease apart without direct sampling of naturally occurring 
isolates from Europe, particularly England, Germany, and 
France, where vaccine strains used worldwide are thought 
to have originated.
Vaccine escape has been hypothesized to account for 
other VACV isolated from domestic animals, including en-
demic buffalopox in India and HSPV (MNR-76) in Mon-
golia (15–18). A limited comparison between the Brazil-
ian sequences and HSPV did not produce a monophyletic 
group, which makes it unlikely that they are derived from 
a very recent common ancestor such as one of the com-
mon vaccine strains developed in the past century. HSPV 
currently has the only complete genome available for com-
parison from a naturally occurring isolate. As the initial 
phylogenetic analysis of this sample suggests, we may ﬁ  nd 
potential sources, such as group 1 of the BRZ-VACV, for 
vaccine strains circulating in various parts of the globe. 
Better sampling of naturally occurring VACV will be es-
sential for determining the existence of indigenous VACV 
in Brazil.
The existence of 2 distinct groups of BRZ-VACV is 
clear. Their origins and how they are related remain unde-
termined. When more data become available, the 2 Brazil-
ian groups may be found to be more closely related than 
illustrated by the tree in Figure 2. No epidemiologic data or 
clinical manifestations that differentiate isolates from the 2 
groups have been reported. Epidemiologic data from recent 
and current zoonotic outbreaks could help elucidate what 
the genomic diversity implies. The data do establish a clear 
connection between group 2 (SAV, BAV, GP1V, and VBH) 
and NYCBH. VACV-WR is strictly a laboratory strain and 
has never been used as a vaccine (29,30). Complete ge-
nome sequencing of BRZ-VACV isolates and a sampling of 
clones from the original seed sample of NYCBH would be 
a dramatic step toward discerning the relationship between 
them. What differentiates the 2 lineages—history, ecology 
or recognizable phenotype—should be further investigat-
ed. The circulation of multiple variants across overlapping 
regions raises the possibility of recombination among vari-
ants, which may complicate the evolutionary history of 
BRZ-VACV.
The certiﬁ  cation of global eradication of smallpox was 
an unprecedented event in human history. However, even 
now, the origins of VACV in nature and as a vaccine remain 
a mystery (3). During the smallpox eradication campaign, 
the dogma held that vaccine strains could not survive in 
nature and that wild-type vaccinia virus was extinct, yet 
VACV clearly persist today in Brazil and other parts of the 
world. If these isolates constitute a recently established 
zoonotic disease, they present a unique opportunity for un-
derstanding how molecular changes, such as recombination 
or other mutations, allow for the adaptation of poxviruses 
to new hosts and ecologic pressures.
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